

DESCRIPTION

Source *E. coli*-derived
Glu26-Ile154, with an N-terminal Met
Accession # Q544C8

N-terminal Sequence Analysis Glu26

Predicted Molecular Mass 15 kDa

SPECIFICATIONS

Activity Measured in a cell proliferation assay using PHA-activated human peripheral blood lymphocytes (PBL). Yokota, T. *et al.* (1986) Proc. Natl. Acad. Sci. USA **83**:5894.
The ED₅₀ for this effect is typically 0.15-0.3 ng/mL.

Endotoxin Level <0.01 EU per 1 µg of the protein by the LAL method.

Purity >97%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Formulation Lyophilized from a 0.2 µm filtered solution in PBS. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution Reconstitute 5 µg vials at 50 µg/mL in sterile PBS. Reconstitute 25 µg or larger vials at 100 µg/mL in sterile PBS.


Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.


DATA

SDS-PAGE



1 µg/lane of Recombinant Mouse IL-7 was resolved with SDS-PAGE under reducing (R) conditions and visualized by silver staining, showing a single band at 17 kDa.

Bioactivity



Recombinant Mouse IL-7 (Catalog # 407-ML/CF) stimulates cell proliferation of PHA-activated human peripheral blood lymphocytes. The ED₅₀ for this effect is typically 0.15-0.3 ng/mL.

BACKGROUND

IL-7 (interleukin-7) is a 25 kDa cytokine of the hemopoietin family that plays important roles in lymphocyte differentiation, proliferation, and survival (1-4). Mouse IL-7 cDNA encodes 154 amino acids (aa) that include a 25 aa signal peptide (4). Mouse IL-7 shares approximately 88% aa sequence identity with rat IL-7 and 58-60% with human, equine, bovine, ovine, porcine, feline and canine IL-7. Human and mouse IL-7 exhibit cross-species activity (2, 3). IL-7 is produced by a wide variety of cells in primary and secondary lymphoid tissues, including stromal epithelial cells of the thymus, bone marrow, and intestines (1, 2, 5). Circulating IL-7 is limiting in healthy animals, but increases during lymphopenia (1, 6). IL-7 signals through a complex of the IL-7 Receptor alpha subunit (IL-7 R α , also known as CD127) with the common γ chain (γ_c) (1). The γ_c is also a subunit of the receptors for IL-2, -4, -9, -15, and -21 (1). IL-7 R α is expressed on double negative (CD4⁻CD8⁻) and CD4⁺ or CD8⁺ single positive naïve and memory T cells, but undergoes IL-7-mediated down-regulation and shedding during antigen-driven T cell proliferation, and is absent on regulatory T cells (1, 2, 6-11). IL-7 contributes to the maintenance of all naïve and memory T cells, mainly by promoting expression of the anti-apoptotic protein Bcl-2 (9-11). It is required for optimal T cell-dendritic cell interaction (6). IL-7 is expressed early in B cell development prior to the appearance of surface IgM (1, 5, 9). In mouse, IL-7 activation of IL-7 R α is critical for both T cell and B cell lineage development, while in humans, it is required for T cell but not for B cell development (4, 9, 12, 13). However, IL-7 functions in both mouse and human pro-B cells to suppress premature Ig light chain recombination during proliferative growth (14, 15).

References:

1. Sasson, S.C. *et al.* (2006) *Curr. Drug Targets* 7:1571.
2. Barata, J.T. *et al.* (2006) *Exp. Hematol.* 34:1133.
3. Goodwin, R.G. *et al.* (1990) *Proc. Natl. Acad. Sci. USA* 86:302.
4. Namen, A.E. *et al.* (1988) *Nature* 333:571.
5. Shalapour, S. *et al.* (2012) *PLoS ONE* 7: e31939.
6. Saini, M. *et al.* (2009) *Blood* 113:5793.
7. Park, J.H. *et al.* (2004) *Immunity* 21:289.
8. Vranjkovic, A. *et al.* (2007) *Int. Immunol.* 19:1329.
9. Sudo, T. *et al.* (1993) *Proc. Natl. Acad. Sci.* 90:9125.
10. Seddon, B. *et al.* (2003) *Nat. Immunol.* 4:680.
11. Schluns, K.S. *et al.* (2000) *Nat. Immunol.* 5:426.
12. Peschon, J.J. *et al.* (1994) *J. Exp. Med.* 180:1955.
13. Pribyl, J.A. and T.W. LeBien (1996) *Proc. Natl. Acad. Sci.* 93:10348.
14. Johnson, K. *et al.* (2012) *J. Immunol.* 188:6084.
15. Nodland, S.E. *et al.* (2011) *Blood* 118:2116.